Crossing the Bridge from ‘Therapeutic Target’ to ‘Asset’
|Please join us to learn about the drug discovery pipeline!
What does it take to get that “potential target for therapy” that you discovered to a marketable product?
Alex Abuin, Ph.D.
Alex Abuin, Ph.D. is currently Executive Director of Portfolio Management at Nurix Therapeutics in San Francisco, California. Alex began his career in pharma as an investigator at SmithKline Beecham Pharmaceuticals, where he was part of the team that established their mouse transgenic and knockout capabilities for drug discovery. He next moved to Lexicon Pharmaceuticals, where he played various roles including Molecular Genetics, Genomics, large scale Target Validation, Research Operations, Alliance Management, Business Development & Investor Relations. Subsequently, Alex was Director of Strategic Industry Ventures at MD Anderson Cancer Center, where he helped establish target discovery and drug development collaborations between MD Anderson and the biopharmaceutical industry. He received his Ph.D. in Molecular and Human Genetics from Baylor College of Medicine and his BS in Biology from the University of North Carolina at Charlotte.